Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection

Il-Yang Pharmaceutical

Status and phase

Completed

Phase 4

Conditions

Helicobacter Infections

Treatments

Drug: Ilaprazole + Amoxicillin

Study type

Interventional

Funder types

Industry

Identifiers

NCT02401477

DUMC-LYJ-ILA01

Details and patient eligibility

About

This study assessed eradication rate of dual therapy with high doses of Ilaprazole 40mg BID and Amoxicillin 750mg QID for 14 days on Helicobacter pylori infection.

Full description

The study performed to assess the eradication rate of H.pylori after 14 days treatment. The treatment is defined as those participants who confirmed on gastric or duodenal ulcer (including scar stage) or gastritis by endoscopy or the participants who received endoscopic treamtment for gastric polyp, gastric adenocarcinoma, confirmed to be H.pylori positive patients by the Biopsy or CLO test or Serological Diagnosis.

Patients administered Ilaprazole 40mg BID and Amoxicillin 750mg QID for 14days. The eradication rate on High dose dual therapy assessed by UBT test at Day 49±7.

Enrollment

90 patients

Sex

All

Ages

19 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject who is confirmed on gastric or duodenal ulcer (including scar stage) by endoscopy or among the participants who received endoscopic treamtment for gastric polyp, gastric adenocarcinoma, confirmed to be H.pylori positive patients by the Biopsy, CLO test and Serological Diagnosis.
Subject who fully understands conditions of clinical trial.
Subject who agrees to participate and spontaneously sign the ICF

Exclusion criteria

Known hypersensitivity to any component of Ilaprazole, Amoxicillin(Penicillin Antibiotics).
Subjects who are taking contraindicated medications for experimental and concomitant drug.
Administrated of PPI, antibiotic medication within 4 weeks prior to commencement of the study.
Pregnant and/or lactating women
Reproductive aged women not using contraception
Uncontrolled diabetics
Uncontrolled hypertension
Uncontrolled liver dysfunction
Uncontrolled kidney dysfunction
Alcoholics
Subjects with a history or possibility of digestive malignancy within 5 years
Subjects with a history of gastrectomy or esophagectomy
Subjects with hereditary diseases such as Galactose intolerance, Lapp lactose deficiency, glucose-galactose malabsorption.
Infectious mononucleosis patients
Subjects participating in a clinical trial before another trial wihin 30 days
Inconsistence judged subject by researcher